Navigation Links
Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients

al information about rupture-prone plaque provided by Lp-PLA2 can help identify which metabolic syndrome patients should be targeted with more aggressive treatment."

A second study presented at the meeting focused on treatment of 55 metabolic syndrome patients with elevated levels of Lp-PLA2 and triglycerides. The results presented by Dr. Robert Rosenson of the University of Michigan showed that three months of treatment with fenofibrate (160 mg/day) reduced Lp-PLA2 levels measured with the PLAC test. Lanman said these findings highlight the opportunity for plaque stabilization with lipid-modifying medication when patients with the metabolic syndrome also have elevated Lp-PLA2. "The PLAC test identifies patients who benefit from lipid-modifying therapy such as fenofibrate to help prevent cardiovascular events," he said.

diaDexus, Inc., a privately held biotechnology company based in South San Francisco, Calif., is focused on the discovery, development, and commercialization of innovative, patent-protected diagnostic products with high clinical value. The PLAC test is a simple blood test that has been cleared for marketing by the Food and Drug Administration as an aid in predicting risk for coronary heart disease and ischemic stroke associated with atherosclerosis. In addition to the PLAC test, diaDexus is developing a pipeline of novel cancer diagnostic tests. For information, visit www.plactest.com or www.diaDexus.com.

Note to editors: The American College of Cardiology's 56th annual scientific session is being held at the Ernest N. Morial Convention Center in New Orleans, March 24-27, 2007. diaDexus' booth number is 1232. For copies of the abstracts, please contact Barbara Sullivan at 714/374-6174.

Contact

Sullivan & Associates
Barbara Sullivan, 714-374-6174
bsullivan@sullivanpr.com
or
diaDexus, Inc.
Christina Andrian, 650-246-6476'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
(Date:12/2/2009)... , NEW YORK, Dec. 2 R...ch report is available in its catalogue: ,, Ar...www.reportlinker.com/p0164303/Arthroscopes---A-Wor...procedures are on rise, owing to their mounting sc...kles, elbow, wrists, and hips, apart from knees. T...
(Date:12/2/2009)... , PALO ALTO, Calif., Dec. 2 /PRNewswire-F...ed that on November 25, 2009, Varian, Inc. filed w...s Annual Report on Form 10-K for the fiscal year e...ccessed through the Company,s web site at www.vari...ings," and then on "10-K" in the table shown. Sto...
(Date:12/2/2009)... , NEW YORK, Dec. 2 R...ch report is available in its catalogue: ,, P...et Trends ,, http://www.reportlinker.com/p0...bal-Market-Trends.html ,, Global pharma indu...easing competition in generic markets, rising cost...
Breaking Medicine Technology:Reportlinker Adds Arthroscopes - A World Market Review 2Reportlinker Adds Arthroscopes - A World Market Review 3Reportlinker Adds Arthroscopes - A World Market Review 4Reportlinker Adds Arthroscopes - A World Market Review 5Reportlinker Adds Arthroscopes - A World Market Review 6Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5Association for Molecular Pathology comments to the SACGHS 49088 1Association for Molecular Pathology comments to the SACGHS 49088 2Income education important factors in heart disease risk 49084 1Income education important factors in heart disease risk 49084 2Safety Kleen Announces 24100 000 Commitment to American Heart Association Start 21 Dallas Heart Walk 49082 1Safety Kleen Announces 24100 000 Commitment to American Heart Association Start 21 Dallas Heart Walk 49082 2
...Bavituximab Equivalent and Irradiated Tumor,Cells ...trols in a,Preclinical Model of Brain Cancer--, LO...wswire-FirstCall/ -- Peregrine Pharmaceuticals, In...veloping targeted,monoclonal antibodies for the tr...ction, today announced preclinical studies,present...
...n to be therapeutically effective in a,mouse model... April 2007 - Santaris Pharma, the Danish,biopharm...,presented encouraging data at the American Associ...geles, showing that SPC2996, the,Company,s RNA Ant...reclinical model of human Chronic Lymphocytic Leuk...
Other Medicine Technology:Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 2Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 3Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 4Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 5Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 6Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 2Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 3Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 4Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 5Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 6
(Date:12/2/2009)...UL, South Korea, Dec. 2 ...Korea Telecom (KT), MacroEye and Qualcomm Incorpor...TM) initiative, today announced the expansion of a...d applications through the "Seoul Family Helper" p... devices to caregivers and senior citizens in orde...
(Date:12/2/2009)..., BOSTON, Dec. 2 The Washington Po...s 8%. According to Coremetrics, a marketing optim...on Cyber Monday compared to Cyber Monday 2008. ,...nte Day Spas who reported today "Cyber Monday web...les rose 59%" - said Tiffany Amorosino, COO of Bel...
(Date:12/2/2009)...angioplasty within 90 minutes of hospital arrival,...thDay News) -- A nationwide program to get faster ...heart attack has dramatically reduced the time bet..., More than three-quarters of people with STEMI...cardiogram pattern that shows major blockage of a ...
(Date:12/2/2009)...used, the greater the sleep disturbances, study fi...s) -- The widely used club drug ecstasy appears to...chers. , "People who use ecstasy need to know t...diate and dangerous problems such as sleep apnea,"... School of Medicine in Baltimore, said in a news r...
(Date:12/2/2009)...olongs life remains unclear, researchers say , ... research suggests that enzyme replacement therapy...e with Fabry disease, a rare illness that affects ...e disease, linked to the lack of an enzyme that he...e fatal because it boosts the risk for a stroke, h...
Breaking Medicine News(10 mins):Health News:Qualcomm, City of Seoul, Korea Telecom and MacroEye Leverage the Power of 3G to Connect Low Income and Disabled Senior Citizens to Caregivers 2Health News:Qualcomm, City of Seoul, Korea Telecom and MacroEye Leverage the Power of 3G to Connect Low Income and Disabled Senior Citizens to Caregivers 3Health News:Qualcomm, City of Seoul, Korea Telecom and MacroEye Leverage the Power of 3G to Connect Low Income and Disabled Senior Citizens to Caregivers 4Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 2Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 3Health News:Heart Attack Treatment Speeds Up Nationwide 2Health News:Heart Attack Treatment Speeds Up Nationwide 3Health News:Ecstasy Users at Higher Risk of Sleep Apnea 2
...eme Court,issued a 4-4 decision which will now all... are injured by a drug. Prior to this decision by ...ppeals had ruled in favor of,Michigan plaintiffs, ...he 2nd Circuit,s decision is now the law of the,co...
... States,Conference of Catholic Bishops (USCCB) wel...uary 27 approval of a new, bipartisan bill to comb...e is expected in March., Bishop Thomas G. Wenski ... Committee on Pro-Life Activities, both,affirmed k...
...Supports Diagnosis and Patient Access to ...arch 3 The Jeffrey Modell Foundation,(JMF) and Ta... to Lucile,Packard Children,s Hospital at Stanford...mpasses more than 150 diseases caused by an,immune...
...tool designed to measure a womans willingness to u... the sexual transmission of HIV), researchers at T... women who have used protective methods in the pas... has not been identified yet, several candidates a...
...fying Core Components of Spine Care Centers ...d CHICAGO, March 3 SpineMark Corporation,and NeuS...tion,s first,comprehensive survey of medical and s...Spine COE (Centers of Excellence) Survey(TM), the ...
...n German . ,, In humans, as in all mammals, sl...ave-sleep (SWS) alternates with dream phases, call...l studies suggest that information is processed an...ction of sleep by revealing overriding principles ...
Other Medicine News:Health News:Catholic Bishops Welcome New Bill for Global HIV/AIDS Relief 2Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 2Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 3Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 4Health News:Researchers develop new tool to predict who will use microbicides 2Health News:Researchers develop new tool to predict who will use microbicides 3Health News:SpineMark, NeuStrategy Partner to Conduct Nation's First Spine COE Survey(TM) 2Health News:SpineMark, NeuStrategy Partner to Conduct Nation's First Spine COE Survey(TM) 3Health News:'Power napping' in pigeons 2
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
Medicine Products: